Title of article :
Three-Year Outcomes Following Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in an Unselected Population With Coronary Artery Disease (from the REWARDS Registry)
Author/Authors :
Hanna، نويسنده , , Nicholas N. and Gaglia Jr.، نويسنده , , Michael A. and Torguson، نويسنده , , Rebecca and Ben-Dor، نويسنده , , Itsik and Gonzalez، نويسنده , , Manuel A. and Collins، نويسنده , , Sara D. and Syed، نويسنده , , Asmir I. and Maluenda، نويسنده , , Gabriel and Kaneshige، نويسنده , , Kimberly and Xue، نويسنده , , Zhenyi and Satler، نويسنده , , Lowell F. and Kent، نويسنده , , Kenneth M.، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2010
Abstract :
The Registry Experience at the Washington Hospital Center with Drug-Eluting Stents (REWARDS) study includes unselected patients with coronary artery disease treated with sirolimus-eluting stents (SESs; n = 2,392) or paclitaxel-eluting stents (PES; n = 1,119). This study aimed to examine the long-term safety profile of the 2 stents in a “real-world” population, especially in relation to stent thrombosis, and to compare differences in the diabetic cohort. Patients were followed for 3 years with regard to major adverse cardiac events (MACEs), including death, Q-wave myocardial infarction, and target lesion revascularization. Rates of stent thrombosis were also studied. Baseline characteristics were similar between stents. Although MACE rates at 3 years were similar (SES 28.1% vs PES 28.9%, p = 0.62), there was a significant difference in unadjusted rates of target lesion revascularization (SES 15.6% vs PES 12.6%, p = 0.03), death (SES 15.7% vs PES 19.0%, p = 0.02), and Q-wave myocardial infarction (SES 0.8% vs PES 2.1%, p = 0.003). After multivariable Cox regression to adjust for confounders, there was no significant difference in overall MACEs. Incidence of stent thrombosis was higher in the SES group (SES 2.2% vs PES 1.6%, p = 0.22), but this was not statistically significant (hazard ratio 1.6, 95% confidence interval 0.8 to 2.9, p = 0.17). Overall, diabetics had a higher MACE rate, but there was no difference between insulin- and noninsulin-dependent diabetics. In conclusion, at 3 years, PES and SES achieved similar results in MACEs and stent thrombosis. This should foster confidence that SES or PES can be compared to second-generation drug-eluting stents without concerns for safety or efficacy.
Journal title :
American Journal of Cardiology
Journal title :
American Journal of Cardiology